...
首页> 外文期刊>Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer >EGFR-mutant lung adenocarcinomas treated first-line with the novel EGFR inhibitor, XL647, can subsequently retain moderate sensitivity to erlotinib.
【24h】

EGFR-mutant lung adenocarcinomas treated first-line with the novel EGFR inhibitor, XL647, can subsequently retain moderate sensitivity to erlotinib.

机译:一线用新型EGFR抑制剂XL647治疗的EGFR突变型肺腺癌随后可保持对厄洛替尼的中等敏感性。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

INTRODUCTION: EGFR-mutant lung cancers are sensitive to EGFR tyrosine kinase inhibitors (TKIs). Unfortunately, they develop resistance, often due to acquisition of a second-site mutation (T790M). Current EGFR TKIs select for T790M in preclinical models of acquired resistance. We explored whether all EGFR TKIs similarly select for the T790M mutation using data from early clinical trials and established in vitro models of acquired resistance. METHODS: We analyzed the clinical characteristics of eight patients with metastatic EGFR-mutant lung adenocarcinoma who were treated first-line with XL647 and then progressed. XL647 is an ATP-competitive inhibitor of EGFR, HER2, KDR, and EPHB4. Additional molecular preclinical studies were performed to characterize resistance. RESULTS: Four patients displayed confirmed partial responses (PRs), three patients had unconfirmed PRs, and one patient displayed stable disease. Only one of five patients' tumor samples available for analysis after disease progression harbored the T790M mutation. Eight patients subsequently received erlotinib, with (n = 3) or without (n = 5) chemotherapy. Three of five patients treated with single-agent erlotinib derived additional benefit, staying on drug up to 9 months. EGFR-mutant PC-9 cells with acquired resistance to XL647 did not harbor the T790M mutation, displayed a distinct mRNA profile from PC-9 cells with T790M-mediated resistance, and were moderately sensitive to erlotinib in growth inhibition assays. Crystal structure analyses of XL647/EGFR T790M did not reveal a different binding mode from that of erlotinib. CONCLUSIONS: The findings of this exploratory study suggest that different EGFR TKIs may select for distinct mechanisms of resistance. These results raise the possibility that different EGFR TKIs could be sequentially used to improve outcomes in patients with EGFR-mutant lung cancer. Further work investigating this hypothesis is warranted.
机译:简介:EGFR突变型肺癌对EGFR酪氨酸激酶抑制剂(TKIs)敏感。不幸的是,它们通常由于获得第二位点突变(T790M)而产生抗药性。当前的EGFR TKI在获得性耐药的临床前模型中选择T790M。我们使用来自早期临床试验的数据探索了是否所有EGFR TKI都相似地选择了T790M突变,并建立了获得性耐药的体外模型。方法:我们分析了一线行XL647治疗然后进展的8例转移性EGFR突变型肺腺癌患者的临床特征。 XL647是EGFR,HER2,KDR和EPHB4的ATP竞争性抑制剂。进行了其他分子临床前研究来表征耐药性。结果:4例患者表现出确定的部分反应(PRs),3例患者未证实PRs,1例表现出稳定的疾病。在疾病进展后,只有五分之一的患者肿瘤样本可用于分析,其中包含T790M突变。八名患者随后接受了厄洛替尼,有(n = 3)或没有(n = 5)化疗。用单药厄洛替尼治疗的五名患者中有三名获得了额外的好处,并且服药时间长达9个月。具有对XL647的抗性的EGFR突变PC-9细胞不具有T790M突变,与具有T790M介导的抗性的PC-9细胞相比,显示出明显的mRNA谱,并且在生长抑制试验中对厄洛替尼具有中等敏感性。 XL647 / EGFR T790M的晶体结构分析未显示出与厄洛替尼不同的结合模式。结论:这项探索性研究的结果表明,不同的EGFR TKIs可能会针对不同的耐药机制进行选择。这些结果增加了可以依次使用不同的EGFR TKI改善EGFR突变型肺癌患者预后的可能性。研究该假设的进一步工作是必要的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号